Laurus Labs Limited

NSE LAURUSLABS.NS

Laurus Labs Limited Shares (Diluted, Weighted) for the year ending March 31, 2024: 539,665,671

Laurus Labs Limited Shares (Diluted, Weighted) is 539,665,671 for the year ending March 31, 2024, a 0.01% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Laurus Labs Limited Shares (Diluted, Weighted) for the year ending March 31, 2023 was 539,600,487, a 0.08% change year over year.
Laurus Labs Limited Shares (Diluted, Weighted) for the year ending March 31, 2022 was 539,169,857, a 0.19% change year over year.
Laurus Labs Limited Shares (Diluted, Weighted) for the year ending March 31, 2021 was 538,124,659, a 0.88% change year over year.
Laurus Labs Limited Shares (Diluted, Weighted) for the year ending March 31, 2020 was 533,453,234, a 0.16% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NSE: LAURUSLABS.NS

Laurus Labs Limited

CEO	Dr. Satyanarayana Chava M.Sc., Ph.D.
IPO Date	Dec. 19, 2016
Location	India
Headquarters	Serene Chambers
Employees	6,007
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. The company was incorporated in 2005 and is based in Hyderabad, India.

Key trends

Past 5 years